Market Overview

UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

Share:
Related BMRN
Is BioMarin Still An Outperform At This Research Firm?
BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Merck KGaA-BioMarin's Kuvan may Undergo Label Update - Analyst Blog (Zacks)

According to a research report published this morning, Citi has increased BioMarin Pharmaceuticals' (NASDAQ: BMRN) PT from $45 to $49.

In the report, Citi said, "We hosted a lunch meeting with mgt that addresses several bear arguments. Overall, the key takeaways are: (1) the long-term tax rate will be lower than expected, (2) GALNS ph 3 should be successful, (3) mgt is talking up BMN-701 and PEG-PAL (both are upside to our TP), and (4) there will be more visibility on BMN-673 (PARP inh for ovarian cancer) in Q4:12. While many investors have been worried about mgt's body language re: GALNS and BMN-701, they seem very upbeat to us. We are raising our TP to $49 (+$4) due to a lower tax rate as their IP is domiciled abroad."

Citi maintains its Buy rating on BioMarin Pharmaceuticals, which closed Friday at $38.

Latest Ratings for BMRN

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Feb 2015CitigroupMaintainsBuy
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: CitiAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters